1
|
Huang KC, Chandra D, McGrath S, Dixit V, Zhang C, Wu J, Tendyke K, Yao H, Hukkanen R, Taylor N, Verbel D, Kim DS, Endo A, Noland TA, Chen Y, Matijevic M, Wang J, Hutz J, Sarwar N, Fang FG, Bao X. Correction: Pharmacologic Activation of STING in the Bladder Induces Potent Antitumor Immunity in Non-Muscle Invasive Murine Bladder Cancer. Mol Cancer Ther 2023; 22:551. [PMID: 37009707 DOI: 10.1158/1535-7163.mct-23-0121] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/04/2023]
|
2
|
Huang KC, Chanda D, McGrath S, Dixit V, Zhang C, Wu J, Tendyke K, Yao H, Hukkanen R, Taylor N, Verbel D, Kim DS, Endo A, Noland TA, Chen Y, Matijevic M, Wang J, Hutz J, Sarwar N, Fang FG, Bao X. Pharmacological Activation of STING in Bladder Induces Potent Anti-tumor Immunity in Non-Muscle Invasive Murine Bladder Cancer. Mol Cancer Ther 2022; 21:914-924. [PMID: 35313332 DOI: 10.1158/1535-7163.mct-21-0780] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/20/2021] [Revised: 01/25/2022] [Accepted: 03/09/2022] [Indexed: 11/16/2022]
Abstract
Schweinfurthins, a class of natural products, have attracted considerable interest for novel therapy development because of their selective and potent anti-proliferative activity against human cancer cells. However, the underlying mechanism is not well understood. Herein, we demonstrated that schweinfurthins preferentially inhibited the proliferation of PTEN deficient cancer cells by indirect inhibition of AKT phosphorylation. Intracellularly, schweinfurthins and their analogs arrested trans-Golgi-network trafficking, likely by binding to oxysterol-binding proteins, leading to an effective inhibition of mTOR/AKT signaling through inducing endoplasmic reticulum stress and suppressing both lipid raft-mediated PI3K activation and mTOR/RheB complex formation. Moreover, schweinfurthins were found to be highly potent toward PTEN-deficient B cell lymphoma cells, and displayed two orders of magnitude lower activity toward normal human peripheral blood mononuclear cells and primary fibroblasts in vitro. These results revealed a previously unrecognized role of schweinfurthins in trans-Golgi-network trafficking and linked mechanistically this cellular effect with mTOR/AKT signaling and with cancer cell survival and growth. Our findings suggest a new opportunity to modulate oncogenic signaling by interfering with TGN trafficking to treat mTOR/AKT-dependent human cancers.
Collapse
Affiliation(s)
| | - Dinesh Chanda
- Johnson & Johnson (United States), Cambridge, MA, United States
| | | | | | - Chi Zhang
- Dewpoint Therapeutics, Boston, United States
| | - Jiayi Wu
- H3biomedicine Inc, United States
| | | | - Huilan Yao
- H3 Biomedicine, Cambridge, United States
| | | | - Noel Taylor
- Eisai (United States), Andover, United States
| | | | | | | | | | - Yu Chen
- Eisai Inc, Cambridge, United States
| | - Mark Matijevic
- Boston Pharmaceuticals, Cambridge, Massachusetts, United States
| | - John Wang
- Eisai (United States), Andover, Massachusetts, United States
| | - Janna Hutz
- Eisai, Inc., Cambridge, MA, United States
| | | | | | - Xingfeng Bao
- H3biomedicine Inc., Cambridge, MA, United States
| |
Collapse
|
3
|
Huang KC, Endo A, McGrath S, Chandra D, Wu J, Kim DS, Albu D, Ingersoll C, Tendyke K, Loiacono K, Noland T, Verbel D, Zhang C, Hao MH, Matijevic M, Dixit V, Hukkanen RR, Hutz J, Wang J, Fang F, Bao X, Kolber-Simonds D, Akram M, Sarwar N. Abstract 3269: Discovery and characterization of E7766, a novel macrocycle-bridged STING agonist with pan-genotypic and potent antitumor activity through intravesical and intratumoral administration. Cancer Res 2019. [DOI: 10.1158/1538-7445.am2019-3269] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Introduction: We report discovery and characterization of E7766, a structurally novel STING agonist, as a potential immunotherapy for solid cancers through intratumoral (IT) administration and for Bacillus Calmette-Guerin (BCG) unresponsive non-muscle invasive bladder cancer (NMIBC) through intravesical (VE) administration.
Methods: E7766 was designed and synthesized to optimize the potency of binding to dimerized STING proteins of different genetic isoforms. The compound was extensively and comparatively characterized in a variety of biochemical, molecular and cellular, in vivo, ex vivo, and primary human tumor and cellular studies for potency, mechanisms and translational biomarkers. Novel preclinical models to mimic orthotopic NMIBC and deep lesion metastasis were developed, and co-crystalization with recombinant proteins of genetic variations was performed.
Results: E7766, a novel Macrocycle-Bridged STING Agonist, showed highly specific and potent agonist activity in both human and mouse STING. In human PBMCs, E7766 demonstrated potent and consistent activity across seven tested human STING genotypes (IC50, 0.15-0.79 μM). By contrast, a reference cyclic dinucleotide STING agonist showed weaker potency and substantial variability across genotypes (IC50, 1.88 μM - >50 μM). Co-crystal structures indicated a structural basis for the superior interactions of E7766 with STING proteins compared with conventional cyclic dinucleotide STING agonists. Intravesical administration of E7766 to a preclinical orthotopic mouse bladder cancer model mimicking the BCG-unresponsive NMIBC demonstrated a dose-dependent and curative activity without serious adverse effects. The anti-tumoral activity was associated with a robust induction of IFNβ, CXCL10 and other downstream effectors of STING pathway inside the bladder cavity. In addition, single IT administration of E7766 to a subcutaneous (SC) tumor in mice bearing dual CT26 tumors in liver and SC lesion cured 90% of animals without recurrence for over 8 months. Those tumor-free animals rejected re-challenge of the same tumor cells in the absence of CD8+ T cells or NK cells, indicating the presence of a highly effective immune memory response following treatment with E7766 independent of either cell population alone.
Conclusions: E7766 is a structurally novel and highly potent STING agonist with pan-genotypic activity, demonstrating curative anti-tumoral activity in murine models of BCG-unresponsive NMIBC and of metastatic tumors in deep lesions. Clinical investigation of E7766 is under discussion.
Citation Format: Kuan-Chun Huang, Atsushi Endo, Shannon McGrath, Dinesh Chandra, Jiayi Wu, Dae-Shik Kim, Diana Albu, Christy Ingersoll, Karen Tendyke, Kara Loiacono, Thomas Noland, David Verbel, Chi Zhang, Ming-Hong Hao, Mark Matijevic, Vaishali Dixit, Renee R. Hukkanen, Janna Hutz, John Wang, Frank Fang, Xingfeng Bao, Donna Kolber-Simonds, Muzaffar Akram, Nadeem Sarwar. Discovery and characterization of E7766, a novel macrocycle-bridged STING agonist with pan-genotypic and potent antitumor activity through intravesical and intratumoral administration [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 3269.
Collapse
Affiliation(s)
| | | | | | | | - Jiayi Wu
- Eisai AiM Institute, Andover, MA
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
4
|
Kolber-Simonds D, Wu J, Majumder U, Custar D, Li D, Du H, Postema MH, Noland T, Hart A, Lai G, Eckley S, Dixit V, Tendyke K, Nomoto K, Woodall-Jappe M, McGonigle S. Abstract 3961: Role for neuropilin1 in mode of action of chlorotoxin. Cancer Res 2018. [DOI: 10.1158/1538-7445.am2018-3961] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Chlorotoxin is an established tumor targeting peptide that naturally occurs in scorpion venom. 131I-labelled chlorotoxin assessed in early phase human glioma clinical trials achieved promising results. A peptide drug conjugate (PDC) composed of chlorotoxin peptide linked to a cytotoxic payload (cryptophycin analog) was used as a tool to probe the tumor targeting mechanism of chlorotoxin. The PDC proved efficacious, yet differential sensitivity was observed in multiple human tumor models. Previously described chlorotoxin targets did not align with observed PDC activity; therefore, studies to further elucidate its mechanism were undertaken. PDC treatment of distinct xenograft models led to a wide range of antitumor activity even though similar levels of active metabolite were present in tumor lysates; thus it was hypothesized that a role for chlorotoxin in uptake may be relevant.
We identified that the endocytic receptor Neuropilin1 (NRP1) binds to chlorotoxin peptide fragments following proteolytic digestion in vitro. NRP1 binding was selective for peptides with a free C-terminal arginine, while native chlorotoxin which has an amidated C-terminal arginine did not bind. Recovery of chlorotoxin from ex vivo tumor lysate revealed its metabolism to a carboxylated C-terminal arginine version of the peptide, capable of binding to NRP1. These data suggest that chlorotoxin acts as a cryptic peptide incapable of binding to NRP1 systemically and only when metabolized in the tumor microenvironment is NRP1 binding revealed.
The expression level of human NRP1 in tumors correlated to the PDC antitumor activity in multiple xenograft models; a wider therapeutic window was observed when NRP1 was highly expressed. Reduction of NRP1 levels in vivo through administration of NRP1 blocking antibodies or by NRP1 knockout in tumor cells blunted PDC antitumor activity while not affecting activity of the cytotoxic payload alone. Reduced PDC antitumor activity correlated with significantly lower levels of active metabolite detected in NRP1-deficient tumors. Together, our findings suggest that chlorotoxin metabolized in the tumor microenvironment binds NRP1 on tumor cells to increase uptake of active metabolite into cells, resulting in enhanced antitumor activity.
The identification of NRP1 as an uptake mechanism for chlorotoxin will enable selection of tumors for treatment with chlorotoxin-based therapeutics.
Citation Format: Donna Kolber-Simonds, Jiayi Wu, Utpal Majumder, Daniel Custar, Danyang Li, Hong Du, Maarten H. Postema, Thomas Noland, Andrew Hart, George Lai, Sean Eckley, Vaishali Dixit, Karen Tendyke, Kenichi Nomoto, Mary Woodall-Jappe, Sharon McGonigle. Role for neuropilin1 in mode of action of chlorotoxin [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2018; 2018 Apr 14-18; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2018;78(13 Suppl):Abstract nr 3961.
Collapse
|
5
|
Guzmán EA, Xu Q, Pitts TP, Mitsuhashi KO, Baker C, Linley PA, Oestreicher J, Tendyke K, Winder PL, Suh EM, Wright AE. Leiodermatolide, a novel marine natural product, has potent cytotoxic and antimitotic activity against cancer cells, appears to affect microtubule dynamics, and exhibits antitumor activity. Int J Cancer 2016; 139:2116-26. [PMID: 27376928 DOI: 10.1002/ijc.30253] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/22/2016] [Revised: 05/12/2016] [Accepted: 06/06/2016] [Indexed: 01/05/2023]
Abstract
Pancreatic cancer, the fourth leading cause of cancer death in the United States, has a negative prognosis because metastasis occurs before symptoms manifest. Leiodermatolide, a polyketide macrolide with antimitotic activity isolated from a deep water sponge of the genus Leiodermatium, exhibits potent and selective cytotoxicity toward the pancreatic cancer cell lines AsPC-1, PANC-1, BxPC-3, and MIA PaCa-2, and potent cytotoxicity against skin, breast and colon cancer cell lines. Induction of apoptosis by leiodermatolide was confirmed in the AsPC-1, BxPC-3 and MIA PaCa-2 cells. Leiodermatolide induces cell cycle arrest but has no effects on in vitro polymerization or depolymerization of tubulin alone, while it enhances polymerization of tubulin containing microtubule associated proteins (MAPs). Observations through confocal microscopy show that leiodermatolide, at low concentrations, causes minimal effects on polymerization or depolymerization of the microtubule network in interphase cells, but disruption of spindle formation in mitotic cells. At higher concentrations, depolymerization of the microtubule network is observed. Visualization of the growing microtubule in HeLa cells expressing GFP-tagged plus end binding protein EB-1 showed that leiodermatolide stopped the polymerization of tubulin. These results suggest that leiodermatolide may affect tubulin dynamics without directly interacting with tubulin and hint at a unique mechanism of action. In a mouse model of metastatic pancreatic cancer, leiodermatolide exhibited significant tumor reduction when compared to gemcitabine and controls. The antitumor activities of leiodermatolide, as well as the proven utility of antimitotic compounds against cancer, make leiodermatolide an interesting compound with potential chemotherapeutic effects that may merit further research.
Collapse
Affiliation(s)
- Esther A Guzmán
- Marine Biomedical and Biotechnology Research, Harbor Branch Oceanographic Institute at Florida Atlantic University Ft. Pierce, FL, 34946
| | - Qunli Xu
- Eisai Research Institute of Boston Inc, Andover, MA, 01810-2441
| | - Tara P Pitts
- Marine Biomedical and Biotechnology Research, Harbor Branch Oceanographic Institute at Florida Atlantic University Ft. Pierce, FL, 34946
| | | | - Cheryl Baker
- Burnett School of Biomedical Sciences, University of Central Florida College of Medicine, Orlando, FL, 32827
| | - Patricia A Linley
- Marine Biomedical and Biotechnology Research, Harbor Branch Oceanographic Institute at Florida Atlantic University Ft. Pierce, FL, 34946
| | | | - Karen Tendyke
- Eisai Research Institute of Boston Inc, Andover, MA, 01810-2441
| | - Priscilla L Winder
- Marine Biomedical and Biotechnology Research, Harbor Branch Oceanographic Institute at Florida Atlantic University Ft. Pierce, FL, 34946
| | - Edward M Suh
- Eisai Research Institute of Boston Inc, Andover, MA, 01810-2441
| | - Amy E Wright
- Marine Biomedical and Biotechnology Research, Harbor Branch Oceanographic Institute at Florida Atlantic University Ft. Pierce, FL, 34946
| |
Collapse
|
6
|
Huang KC, Chen Z, Jiang Y, Akare S, Kolber-Simonds D, Condon K, Agoulnik S, Tendyke K, Shen Y, Wu KM, Mathieu S, Choi HW, Zhu X, Shimizu H, Kotake Y, Gerwick WH, Uenaka T, Woodall-Jappe M, Nomoto K. Apratoxin A Shows Novel Pancreas-Targeting Activity through the Binding of Sec 61. Mol Cancer Ther 2016; 15:1208-16. [PMID: 27196783 DOI: 10.1158/1535-7163.mct-15-0648] [Citation(s) in RCA: 45] [Impact Index Per Article: 5.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/04/2015] [Accepted: 03/16/2016] [Indexed: 11/16/2022]
Abstract
Apratoxin A is a natural product with potent antiproliferative activity against many human cancer cell lines. However, we and other investigators observed that it has a narrow therapeutic window in vivo Previous mechanistic studies have suggested its involvement in the secretory pathway as well as the process of chaperone-mediated autophagy. Still the link between the biologic activities of apratoxin A and its in vivo toxicity has remained largely unknown. A better understanding of this relationship is critically important for any further development of apratoxin A as an anticancer drug. Here, we describe a detailed pathologic analysis that revealed a specific pancreas-targeting activity of apratoxin A, such that severe pancreatic atrophy was observed in apratoxin A-treated animals. Follow-up tissue distribution studies further uncovered a unique drug distribution profile for apratoxin A, showing high drug exposure in pancreas and salivary gland. It has been shown previously that apratoxin A inhibits the protein secretory pathway by preventing cotranslational translocation. However, the molecule targeted by apratoxin A in this pathway has not been well defined. By using a (3)H-labeled apratoxin A probe and specific Sec 61α/β antibodies, we identified that the Sec 61 complex is the molecular target of apratoxin A. We conclude that apratoxin A in vivo toxicity is likely caused by pancreas atrophy due to high apratoxin A exposure. Mol Cancer Ther; 15(6); 1208-16. ©2016 AACR.
Collapse
Affiliation(s)
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | - William H Gerwick
- Center for Marine Biotechnology and Biomedicine, Scripps Institution of Oceanography and the Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California San Diego, La Jolla, California
| | | | | | | |
Collapse
|
7
|
Thomas AG, Sattler R, Tendyke K, Loiacono KA, Hansen H, Sahni V, Hashizume Y, Rojas C, Slusher BS. High-Throughput Assay Development for Cystine-Glutamate Antiporter (xc-) Highlights Faster Cystine Uptake than Glutamate Release in Glioma Cells. PLoS One 2015; 10:e0127785. [PMID: 26252954 PMCID: PMC4529246 DOI: 10.1371/journal.pone.0127785] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/09/2014] [Accepted: 04/19/2015] [Indexed: 01/22/2023] Open
Abstract
The cystine-glutamate antiporter (system xc-) is a Na+-independent amino acid transporter that exchanges extracellular cystine for intracellular glutamate. It is thought to play a critical role in cellular redox processes through regulation of intracellular glutathione synthesis via cystine uptake. In gliomas, system xc- expression is universally up-regulated while that of glutamate transporters down-regulated, leading to a progressive accumulation of extracellular glutamate and excitotoxic cell death of the surrounding non-tumorous tissue. Additionally, up-regulation of system xc- in activated microglia has been implicated in the pathogenesis of several neurodegenerative disorders mediated by excess glutamate. Consequently, system xc- is a new drug target for brain cancer and neuroinflammatory diseases associated with excess extracellular glutamate. Unfortunately no potent and selective small molecule system xc- inhibitors exist and to our knowledge, no high throughput screening (HTS) assay has been developed to identify new scaffolds for inhibitor design. To develop such an assay, various neuronal and non-neuronal human cells were evaluated as sources of system xc-. Human glioma cells were chosen based on their high system xc- activity. Using these cells, [14C]-cystine uptake and cystine-induced glutamate release assays were characterized and optimized with respect to cystine and protein concentrations and time of incubation. A pilot screen of the LOPAC/NINDS libraries using glutamate release demonstrated that the logistics of the assay were in place but unfortunately, did not yield meaningful pharmacophores. A larger, HTS campaign using the 384-well cystine-induced glutamate release as primary assay and the 96-well 14C-cystine uptake as confirmatory assay is currently underway. Unexpectedly, we observed that the rate of cystine uptake was significantly faster than the rate of glutamate release in human glioma cells. This was in contrast to the same rates of cystine uptake and glutamate release previously reported in normal human fibroblast cells.
Collapse
Affiliation(s)
- Ajit G. Thomas
- Brain Science Institute, Johns Hopkins University School of Medicine, Baltimore, MD, 21205, United States of America
| | - Rita Sattler
- Brain Science Institute, Johns Hopkins University School of Medicine, Baltimore, MD, 21205, United States of America
- Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD, 21205, United States of America
| | - Karen Tendyke
- Next Generation Systems CFU, Eisai Inc., Andover, MA, 01810, United States of America
| | - Kara A. Loiacono
- Next Generation Systems CFU, Eisai Inc., Andover, MA, 01810, United States of America
| | - Hans Hansen
- Next Generation Systems CFU, Eisai Inc., Andover, MA, 01810, United States of America
| | - Vishal Sahni
- Neuroscience and General Medicine PCU, Eisai Inc., Andover, MA, 01810, United States of America
| | - Yutaka Hashizume
- Neuroscience and General Medicine PCU, Eisai Inc., Andover, MA, 01810, United States of America
| | - Camilo Rojas
- Brain Science Institute, Johns Hopkins University School of Medicine, Baltimore, MD, 21205, United States of America
- Department of Comparative Medicine and Molecular Pathobiology, Johns Hopkins University School of Medicine, Baltimore, MD, 21205, United States of America
- * E-mail: (CR); (BSS)
| | - Barbara S. Slusher
- Brain Science Institute, Johns Hopkins University School of Medicine, Baltimore, MD, 21205, United States of America
- Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD, 21205, United States of America
- Department of Psychiatry, Johns Hopkins University School of Medicine, Baltimore, MD, 21205, United States of America
- Department of Neuroscience, Johns Hopkins University School of Medicine, Baltimore, MD, 21205, United States of America
- * E-mail: (CR); (BSS)
| |
Collapse
|
8
|
Bao X, Zheng W, Hata Sugi N, Agarwala KL, Xu Q, Wang Z, Tendyke K, Lee W, Parent L, Li W, Cheng H, Shen Y, Taylor N, Dezso Z, Du H, Kotake Y, Zhao N, Wang J, Postema M, Woodall-Jappe M, Takase Y, Uenaka T, Kingston DGI, Nomoto K. Small molecule schweinfurthins selectively inhibit cancer cell proliferation and mTOR/AKT signaling by interfering with trans-Golgi-network trafficking. Cancer Biol Ther 2015; 16:589-601. [PMID: 25729885 DOI: 10.1080/15384047.2015.1019184] [Citation(s) in RCA: 23] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
Abstract
Natural compound schweinfurthins are of considerable interest for novel therapy development because of their selective anti-proliferative activity against human cancer cells. We previously reported the isolation of highly active schweinfurthins E-H, and in the present study, mechanisms of the potent and selective anti-proliferation were investigated. We found that schweinfurthins preferentially inhibited the proliferation of PTEN deficient cancer cells by indirect inhibition of AKT phosphorylation. Mechanistically, schweinfurthins and their analogs arrested trans-Golgi-network trafficking, an intracellular vesicular trafficking system, resulting in the induction of endoplasmic reticulum stress and the suppression of both lipid raft-mediated PI3K activation and mTOR/RheB complex formation, which collectively led to an effective inhibition of mTOR/AKT signaling. The trans-Golgi-network traffic arresting effect of schweinfurthins was associated with their in vitro binding activity to oxysterol-binding proteins that are known to regulate intracellular vesicular trafficking. Moreover, schweinfurthins were found to be highly toxic toward PTEN-deficient B cell lymphoma cells, and displayed 2 orders of magnitude lower activity toward normal human peripheral blood mononuclear cells and primary fibroblasts in vitro. These results revealed a previously unrecognized role of schweinfurthins in regulating trans-Golgi-network trafficking, and linked mechanistically this cellular effect with mTOR/AKT signaling and with cancer cell survival and growth. Our findings suggest the schweinfurthin class of compounds as a novel approach to modulate oncogenic mTOR/AKT signaling for cancer treatment.
Collapse
|
9
|
Ortega HE, Graupner PR, Asai Y, Tendyke K, Qiu D, Shen YY, Rios N, Arnold AE, Coley PD, Kursar TA, Gerwick WH, Cubilla-Rios L. Mycoleptodiscins A and B, cytotoxic alkaloids from the endophytic fungus Mycoleptodiscus sp. F0194. J Nat Prod 2013; 76:741-744. [PMID: 23560689 DOI: 10.1021/np300792t] [Citation(s) in RCA: 24] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/28/2023]
Abstract
Two novel reddish-orange alkaloids, mycoleptodiscin A (1) and mycoleptodiscin B (2), were isolated from liquid cultures of the endophytic fungus Mycoleptodiscus sp. that had been isolated from Desmotes incomparabilis in Panama. Elucidation of their structures was accomplished using 1D and 2D NMR spectroscopy in combination with IR spectroscopic and MS data. These compounds are indole-terpenes with a new skeleton uncommon in nature. Mycoleptodiscin B (2) was active in inhibiting the growth of cancer cell lines with IC50 values in the range 0.60-0.78 μM.
Collapse
Affiliation(s)
- Humberto E Ortega
- Laboratory of Tropical Bioorganic Chemistry, Faculty of Natural, Exact Science and Technology, University of Panama, Panama
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
10
|
Yu MJ, Zheng W, Tendyke K. Atom-based enumeration: new eribulin analogues with low susceptibility to P-glycoprotein-mediated drug efflux. Bioorg Med Chem Lett 2012; 22:7363-6. [PMID: 23141916 DOI: 10.1016/j.bmcl.2012.10.077] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/28/2012] [Revised: 10/08/2012] [Accepted: 10/15/2012] [Indexed: 11/17/2022]
Abstract
A series of eribulin analogues was evolved in silico through iterative atom-based enumeration employing a genetic algorithm-derived survival function to minimize predicted PgP-mediated drug efflux. Representatives of the virtual series were subsequently synthesized in the laboratory and tested in vitro for PgP-susceptibility. These new computer-inspired derivatives were found to exhibit high cell growth inhibitory activity and to be among the least sensitive to P-glycoprotein-mediated drug efflux in the eribulin series, thereby validating this approach to in silico molecular design.
Collapse
Affiliation(s)
- Melvin J Yu
- Eisai Inc., 4 Corporate Dr., Andover, MA 01810, USA.
| | | | | |
Collapse
|
11
|
Xu Q, Huang KC, Tendyke K, Marsh J, Liu J, Qiu D, Littlefield BA, Nomoto K, Atasoylu O, Risatti CA, Sperry JB, Smith AB. In vitro and in vivo anticancer activity of (+)-spongistatin 1. Anticancer Res 2011; 31:2773-9. [PMID: 21868519 PMCID: PMC3181053] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/31/2023]
Abstract
The marine natural product (+)-spongistatin 1 is an extremely potent growth inhibitory agent having activity against a wide variety of cancer cell lines, while exhibiting low cytotoxicity against quiescent human fibroblasts. Consistent with a microtubule-targeting mechanism of action, (+)-spongistatin 1 causes mitotic arrest in DU145 human prostate cancer cells. More importantly, (+)-spongistatin 1 exhibits significant in vivo antitumor activity in the LOX-IMVI human melanoma xenograft model. (+)-Spongistatin 1 is, thus, an important class of microtubule targeting anticancer agent that warrants further investigation.
Collapse
Affiliation(s)
- Qunli Xu
- Eisai Inc., 4 Corporate Drive, Andover, MA 01810, USA.
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
12
|
Narayan S, Carlson EM, Cheng H, Condon K, Du H, Eckley S, Hu Y, Jiang Y, Kumar V, Lewis BM, Saxton P, Schuck E, Seletsky BM, Tendyke K, Zhang H, Zheng W, Littlefield BA, Towle MJ, Yu MJ. Novel second generation analogs of eribulin. Part II: Orally available and active against resistant tumors in vivo. Bioorg Med Chem Lett 2011; 21:1634-8. [DOI: 10.1016/j.bmcl.2011.01.097] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/16/2010] [Accepted: 01/20/2011] [Indexed: 02/06/2023]
|
13
|
Narayan S, Carlson EM, Cheng H, Du H, Hu Y, Jiang Y, Lewis BM, Seletsky BM, Tendyke K, Zhang H, Zheng W, Littlefield BA, Towle MJ, Yu MJ. Novel second generation analogs of eribulin. Part I: Compounds containing a lipophilic C32 side chain overcome P-glycoprotein susceptibility. Bioorg Med Chem Lett 2011; 21:1630-3. [PMID: 21324686 DOI: 10.1016/j.bmcl.2011.01.111] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/16/2010] [Revised: 01/22/2011] [Accepted: 01/25/2011] [Indexed: 11/29/2022]
Abstract
Eribulin mesylate (Halaven™), a totally synthetic analog of the marine polyether macrolide halichondrin B, has recently been approved in the United States as a treatment for breast cancer. It is also currently under regulatory review in Japan and the European Union. Our continuing medicinal chemistry efforts on this scaffold have focused on oral bioavailability, brain penetration and efficacy against multidrug resistant (MDR) tumors by lowering the susceptibility of these compounds to P-glycoprotein (P-gp)-mediated drug efflux. Replacement of the 1,2-amino alcohol C32 side chain of eribulin with fragments neutral at physiologic pH led to the identification of analogs with significantly lower P-gp susceptibility. The analogs maintained low- to sub-nM potency in vitro against both sensitive and MDR cell lines. Within this series, increasing lipophilicity generally led to decreased P-gp susceptibility. In addition to potency in cell culture, these compounds showed in vivo activity in mouse xenograft models.
Collapse
Affiliation(s)
- Sridhar Narayan
- Eisai Product Creation Systems, Eisai Inc., Andover, MA 01810, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
14
|
Pan E, Harinantenaina L, Brodie PJ, Callmander M, Rakotonandrasana S, Rakotobe E, Rasamison VE, Tendyke K, Shen Y, Suh EM, Kingston DGI. Cardenolides of Leptadenia madagascariensis from the Madagascar dry forest. Bioorg Med Chem 2010; 19:422-8. [PMID: 21159516 DOI: 10.1016/j.bmc.2010.11.021] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/06/2010] [Revised: 11/03/2010] [Accepted: 11/05/2010] [Indexed: 11/30/2022]
Abstract
Investigation of the endemic Madagascar plant Leptadenia madagascariensis Decne. (Apocynaceae) for antiproliferative activity against the A2780 ovarian cancer cell line led to the isolation of the four new cardenolides 1-4. The structure elucidations of these compounds were based on analyzes of their 1D and 2D NMR spectra and mass spectrometric data. The cardenolides were strongly antiproliferative to the A2780 ovarian cancer cell line, with IC(50) values of 0.18, 0.21, 0.17, and 0.29μM line, and to the H460 human lung cancer cell line, with IC(50) values of 0.16, 0.68, 0.37, and 0.48μM, respectively.
Collapse
Affiliation(s)
- Ende Pan
- Department of Chemistry, M/C 0212, Virginia Polytechnic Institute and State University, Blacksburg, VA 24061, United States
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
15
|
Harinantenaina L, Brodie PJ, Slebodnick C, Callmander MW, Rakotobe E, Randrianasolo S, Randrianaivo R, Rasamison VE, Tendyke K, Shen Y, Suh EM, Kingston DGI. Antiproliferative compounds from Pongamiopsis pervilleana from the Madagascar Dry Forest. J Nat Prod 2010; 73:1559-62. [PMID: 20804165 PMCID: PMC2945424 DOI: 10.1021/np100430r] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/29/2023]
Abstract
Bioassay-guided fractionation of an ethanol extract of the roots of the endemic Malagasy plant Pongamiopsis pervilleana led to the isolation of the three new compounds (2'R)-4'-hydroxyemoroidocarpan (1), pongavilleanine (3), and epipervilline (4) together with two known compounds, identified as emoroidocarpan (2) and rotenolone (5). The structures of all compounds were determined by physical, chemical, and spectroscopic evidence. The stereochemistry at C-2' of the previously reported compound emoroidocarpan was determined to be R by the observation of a negative Cotton effect at 474 nm in the CD spectrum of its osmate ester derivative. Compounds 2-5 displayed moderate antiproliferative activity against the A2780 human ovarian cancer cell line, and rotenolone also showed micromolar antiproliferative activity toward the breast cancer BT-549, prostate cancer DU 145, NSCLC NCI-H460, and colon cancer HCC-2998 cell lines.
Collapse
Affiliation(s)
- Liva Harinantenaina
- Department of Chemistry, M/C 0212, Virginia Polytechnic Institute and State University, Blacksburg, Virginia 24061-0212, USA
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
16
|
Smith AB, Risatti CA, Atasoylu O, Bennett CS, Tendyke K, Xu Q. Design, synthesis, and biological evaluation of EF- and ABEF- analogues of (+)-spongistatin 1. Org Lett 2010; 12:1792-5. [PMID: 20297810 PMCID: PMC2853872 DOI: 10.1021/ol100418n] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
The design, synthesis, and biological evaluation of two potential (+)-spongistatin 1 analogues have been achieved. The analogues, incorporating tethers (red) in place of the ABCD and the CD components of the (+)-spongistatin 1 macrolide, were designed such that the conformations of the retained skeleton (blue) would mimic the assigned major solution conformation of the natural product The nanomolar cytotoxicity observed for the ABEF analogue provides strong support for the assigned solution conformation.
Collapse
Affiliation(s)
- Amos B Smith
- Department of Chemistry, Monell Chemical Senses Center and Laboratory for Research on the Structure of Matter, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA.
| | | | | | | | | | | |
Collapse
|
17
|
Kuznetsov G, Xu Q, Rudolph-Owen L, Tendyke K, Liu J, Towle M, Zhao N, Marsh J, Agoulnik S, Twine N, Parent L, Chen Z, Shie JL, Jiang Y, Zhang H, Du H, Boivin R, Wang Y, Romo D, Littlefield BA. Potent in vitro and in vivo anticancer activities of des-methyl, des-amino pateamine A, a synthetic analogue of marine natural product pateamine A. Mol Cancer Ther 2009; 8:1250-60. [PMID: 19417157 DOI: 10.1158/1535-7163.mct-08-1026] [Citation(s) in RCA: 77] [Impact Index Per Article: 5.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
We report here that des-methyl, des-amino pateamine A (DMDA-PatA), a structurally simplified analogue of the marine natural product pateamine A, has potent antiproliferative activity against a wide variety of human cancer cell lines while showing relatively low cytotoxicity against nonproliferating, quiescent human fibroblasts. DMDA-PatA retains almost full in vitro potency in P-glycoprotein-overexpressing MES-SA/Dx5-Rx1 human uterine sarcoma cells that are significantly resistant to paclitaxel, suggesting that DMDA-PatA is not a substrate for P-glycoprotein-mediated drug efflux. Treatment of proliferating cells with DMDA-PatA leads to rapid shutdown of DNA synthesis in the S phase of the cell cycle. Cell-free studies show that DMDA-PatA directly inhibits DNA polymerases α and γ in vitro albeit at concentrations considerably higher than those that inhibit cell proliferation. DMDA-PatA shows potent anticancer activity in several human cancer xenograft models in nude mice, including significant regressions observed in the LOX and MDA-MB-435 melanoma models. DMDA-PatA thus represents a promising natural product-based anticancer agent that warrants further investigation.
Collapse
Affiliation(s)
- Galina Kuznetsov
- Division of Biological Research, and 3Scientific Administration, Eisai Research Institute of Boston, Inc, Andover, Massachusetts 01810, USA
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
18
|
Murphy BT, Cao S, Brodie PJ, Miller JS, Ratovoson F, Birkinshaw C, Rakotobe E, Rasamison VE, Tendyke K, Suh EM, Kingston DGI. Antiproliferative compounds of Artabotrys madagascariensis from the Madagascar rainforest. Nat Prod Res 2008; 22:1169-75. [PMID: 18855218 PMCID: PMC2786269 DOI: 10.1080/14786410701726525] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
Abstract
Bioassay-guided fractionation of an ethanol extract of Artabotrys madagascariensis led to the isolation of the new compound artabotrene (1), two butenolides (2 and 3), and the tetracyclic triterpene polycarpol (4). Structure elucidation was determined on the basis of one and two-dimensional NMR, and absolute configuration of compounds 2-4 was verified by analysis of CD and optical rotation spectra. Two of the isolates, melodorinol (2) and acetylmelodorinol (3), were found to display antiproliferative activity against five different tumour cell lines with IC50 values ranging from 2.4 to 12 microM.
Collapse
Affiliation(s)
- Brian T. Murphy
- Department of Chemistry, M/C 0212, Virginia Polytechnic Institute and State University, Blacksburg, VA 24061-0212, USA
| | - Shugeng Cao
- Department of Chemistry, M/C 0212, Virginia Polytechnic Institute and State University, Blacksburg, VA 24061-0212, USA
| | - Peggy J. Brodie
- Department of Chemistry, M/C 0212, Virginia Polytechnic Institute and State University, Blacksburg, VA 24061-0212, USA
| | - James S. Miller
- Missouri Botanical Garden, P.O. Box 299, St. Louis Missouri 63166-0299
| | - Fidy Ratovoson
- Missouri Botanical Garden, P.O. Box 299, St. Louis Missouri 63166-0299
| | - Chris Birkinshaw
- Missouri Botanical Garden, P.O. Box 299, St. Louis Missouri 63166-0299
| | - Etienne Rakotobe
- Centre National d’Application et Recherches Pharmaceutiques, B.P 702, Antananarivo 101, Madagascar
| | - Vincent E. Rasamison
- Centre National d’Application et Recherches Pharmaceutiques, B.P 702, Antananarivo 101, Madagascar
| | - Karen Tendyke
- Eisai Research Institute, 4 Corporate Drive, Andover, MA 01810-2441, USA
| | - Edward M. Suh
- Eisai Research Institute, 4 Corporate Drive, Andover, MA 01810-2441, USA
| | - David G. I. Kingston
- Department of Chemistry, M/C 0212, Virginia Polytechnic Institute and State University, Blacksburg, VA 24061-0212, USA
| |
Collapse
|
19
|
Agoulnik S, Kuznetsov G, Tendyke K, Parent LA, Marsh JP, Twine N, Renshaw FG, Silberman S, Littlefield BA. Sensitivity to halichondrin analog E7389 and hemiasterlin analog E7974 correlates with βIII tubulin isotype expression in human breast cancer cell lines. J Clin Oncol 2005. [DOI: 10.1200/jco.2005.23.16_suppl.2012] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- S. Agoulnik
- Eisai Research Inst, Andover, MA; Eisai Medcl Research, Ridgefield Park, NJ
| | - G. Kuznetsov
- Eisai Research Inst, Andover, MA; Eisai Medcl Research, Ridgefield Park, NJ
| | - K. Tendyke
- Eisai Research Inst, Andover, MA; Eisai Medcl Research, Ridgefield Park, NJ
| | - L. A. Parent
- Eisai Research Inst, Andover, MA; Eisai Medcl Research, Ridgefield Park, NJ
| | - J. P. Marsh
- Eisai Research Inst, Andover, MA; Eisai Medcl Research, Ridgefield Park, NJ
| | - N. Twine
- Eisai Research Inst, Andover, MA; Eisai Medcl Research, Ridgefield Park, NJ
| | - F. G. Renshaw
- Eisai Research Inst, Andover, MA; Eisai Medcl Research, Ridgefield Park, NJ
| | - S. Silberman
- Eisai Research Inst, Andover, MA; Eisai Medcl Research, Ridgefield Park, NJ
| | - B. A. Littlefield
- Eisai Research Inst, Andover, MA; Eisai Medcl Research, Ridgefield Park, NJ
| |
Collapse
|